Spinal subependymoma surgery: do no harm. Little may be more!


Journal

Neurosurgical review
ISSN: 1437-2320
Titre abrégé: Neurosurg Rev
Pays: Germany
ID NLM: 7908181

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 07 03 2019
accepted: 30 05 2019
revised: 23 05 2019
pubmed: 20 6 2019
medline: 27 11 2020
entrez: 20 6 2019
Statut: ppublish

Résumé

 Outline the reported diagnostic and operative findings, and evaluate the surgical treatment outcome to clarify the best available recommendations.  Ovid Medline, Embase and PubMed central databases were searched from inception until January 2019 using the terms (subependymoma and (spinal or cervical or thoracic)). The articles were reviewed for reported spinal subependymoma cases perioperative management and treatment outcomes.  A total of 49 papers provided data on 105 cases. 47 cases were reported in the last 5 years. The reported cases were two medullary-cervical, 35 cervical, 32 cervicothoracic, 21 thoracic, 12 thoracolumbar and three lumbar. Spinal subependymomas typically arise from within the central spinal canal, giving the appearance of an intramedullary mass, usually eccentric to one side. Symptoms at presentation ranged between 1 month to 17 years, (mean 3.5 years, median 2 years) and were over 3 years in 36, and over 8 years in 12 cases. Sensory symptoms are the most frequent 75(80%), followed by weakness in 60(64%), pain in 45(48%) and sphincter disturbance in 24(25%). Postoperative neurological function was reported in 78 cases, and worsening was reported in 40 cases (51%), of which, 29 (72%) had complete resection, 6 (15%) had subtotal resection and 5 (12%) had partial resection. Neurological status remained the same in 24 (30%) and improved in 14 (18%).  The reviewed cases report a rate of 65% total resection of which 57% had worsened function after surgery. There were no reports of malignant transformation; therefore, long-term survival is expected, and surgical caution should be exercised where there is minimal symptom progression.

Identifiants

pubmed: 31214945
doi: 10.1007/s10143-019-01128-x
pii: 10.1007/s10143-019-01128-x
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1047-1053

Auteurs

Hamzah A Soleiman (HA)

Department of Clinical Neurosciences-Neurosurgery, Lothian University Hospitals NHS trust, Edinburgh, UK. h.a.soleiman@gmail.com.

James Ironside (J)

Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.

Susan Kealey (S)

Department of Neuroradiology, Lothian University Hospitals NHS trust, Edinburgh, UK.

Andreas K Demetriades (AK)

Department of Clinical Neurosciences-Neurosurgery, Lothian University Hospitals NHS trust, Edinburgh, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH